@article{1867e2317e4549b1b7ec11a321cc580b,
title = "An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies",
author = "A. Blauvelt and M. Ramharter and Cohen, {A. D.} and W. Xu and H. Patel and C. Schuster and E. Riedl and L. Puig",
note = "Funding Information: Eli Lilly and Company (Indianapolis, Indiana, USA) sponsored this study. Medical writing assistance was provided by Gerard Sheehan, PhD. AB has served as a scientific adviser and/or clinical study investigator for AbbVie, Aligos, Almirall, Amgen, Arcutis, Arena, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma and UCB Pharma. MR has no conflict of interest disclosures. AC has served as an advisor, investigator, or speaker for Abbvie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer and Rafa. LP has received grants or research support or participated in clinical trials (paid to institution) from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Eli Lilly and Company, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB; honoraria or consultation fees (paid to self) from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Eli Lilly and Company, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB; and has been a speaker for Celgene, Janssen, Eli Lilly and Company, MSD, Novartis and Pfizer. WX, HP, CS and ER are employees of and are minor shares in Eli Lilly and Company.",
year = "2021",
month = nov,
day = "1",
doi = "10.1111/jdv.17554",
language = "English",
volume = "35",
pages = "e828--e831",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "11",
}
